KDR and breast carcinoma: We found that cell lines with low expression of FBXW7 were more sensitive to Cabozentanib (P-value = 0.033) (Fig. 3b, c), which supports our hypothesis that inhibition of VEGFR should mimic the SLI between FBXW7 and RPE. Unfortunately, our classification of cell lines based on FBXW7 expression for only breast cancer cell lines did not yield sufficient sample size.